Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

HKG:2566 Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	139.5	138.41	138.6	119.78	59.87	119.41
Depreciation & Amortization	39.53	37.91	36.22	35.82	35.77	24.24
Other Amortization	6.66	6.66	0.72	0.32	-	-
Loss (Gain) From Sale of Assets	0.07	0.07	0.27	0.41	0.04	0.33
Loss (Gain) From Sale of Investments	-4.91	2.83	6.5	1.22	0.46	-0.08
Stock-Based Compensation	4.59	5.55	5.3	11.93	0.18	0.15
Other Operating Activities	8.69	-4.33	26.24	26.62	12.74	7.24
Change in Accounts Receivable	183.64	23.57	-144.3	-62.47	-82.03	-131.24
Change in Inventory	-6.68	-6.99	11.39	0.91	27.79	49.16
Change in Accounts Payable	-27.33	21.38	-15.42	-9.22	-14.8	-32.69
Change in Unearned Revenue	8.73	-0.99	7.59	-2.15	-5.03	1.19
Change in Other Net Operating Assets	-2.85	30.79	21.68	12.61	-12.41	29.83
Operating Cash Flow	349.64	254.84	94.79	135.77	22.56	67.53
Operating Cash Flow Growth	191.75%	168.86%	-30.19%	501.82%	-66.59%	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-125.57	-49.59	-15.09	-21.1	-23.3	-53.94
Sale of Property, Plant & Equipment	0.44	0.08	0.12	0	0.01	0.05
Sale (Purchase) of Intangibles	-42.24	-55.06	-64.76	-25.88	-35.66	-8.97
Investment in Securities	0.01	-300	-	-	-	-
Investing Cash Flow	-163.47	-404.57	-79.73	-46.98	-58.94	-62.86

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	114.9	130.2	143.31	204.17	209.62
Long-Term Debt Repaid	-	-136.07	-176.55	-196.16	-170.3	-158.65
Lease Payments	-5.79	-3.97	-0.85	-1.18	-0.33	-0.32
Net Debt Issued (Repaid)	-10.46	-21.17	-46.35	-52.86	33.88	50.97
Issuance of Common Stock	-	-	521	-	-	-
Common Dividends Paid	-12.17	-13.73	-	-	-12	-
Other Financing Activities	-4.82	-4.54	-46.34	-14.49	-8.98	-9.75
Financing Cash Flow	-68.03	-39.45	428.32	-67.35	12.89	41.23

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-4.33	0.22	1.08	0.21	0.2	-0.12
Net Cash Flow	113.81	-188.96	444.45	21.64	-23.29	45.78

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	224.07	205.25	79.69	114.66	-0.74	13.59
Free Cash Flow Growth	118.53%	157.56%	-30.50%	-	-	-
Free Cash Flow Margin	17.26%	15.71%	5.82%	8.91%	-0.07%	1.04%
Free Cash Flow Per Share	0.92	0.84	0.39	0.57	-0.00	0.07
Levered Free Cash Flow	87.55	83.85	14.91	12.11	-51.21	-
Unlevered Free Cash Flow	91.19	87.39	19.37	17.98	-45.56	-
Free Cash Flow After Leases	218.28	201.28	78.85	113.48	-1.07	13.26

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	3.83	4.5	7.15	9.41	8.98	9.75
Cash Income Tax Paid	19.7	31.37	19.16	-1.1	-10.5	11.74
Change in Working Capital	155.51	67.76	-119.06	-60.32	-86.5	-83.76

Data Source: S&P Global Market Intelligence Last updated: Sep 23, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 9, 2026

Data Sources Report a data error